Honeywell International Indefinite-Lived Research and Development Assets decreased by 2.0% to $386.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.1%, from $439.00M to $386.00M. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -17.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q4 '21 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.01B | $953.00M | $971.00M | $971.00M | $971.00M | $440.00M | $414.00M | $439.00M | $430.00M | $426.00M | $394.00M | $386.00M |
| QoQ Change | — | -6.0% | +1.9% | +0.0% | +0.0% | -54.7% | -5.9% | +6.0% | -2.1% | -0.9% | -7.5% | -2.0% |
| YoY Change | — | -6.0% | +1.9% | — | — | — | -57.4% | -54.8% | -55.7% | -3.2% | -4.8% | -12.1% |